This microfluidic encapsulation technology is ideal for gene silencing applications in cancer immunology and inflammatory diseases, where siRNA can potentially be used to down-regulate genes associated with these pathologies. Prof. Dr. Olivia Merkel, Professor of Drug Delivery, explained: “Nanoencapsulation is a highly efficient way to deliver siRNA to targets across the cellular membrane, protecting it from degradation prior to endocytosis. It is important to deliver the therapy in a controlled and reproducible manner; the particle size has a huge impact on in vivo work, affecting the rate of uptake and clearance.”
“Previously, we produced our nanoparticles manually, which was both time consuming and uncontrolled, and resulted in a range of particle diameters. We needed a solution to overcome this challenge and, in 2017, discovered Dolomite Microfluidics. We’ve been using Dolomite chips ever since, consistently downsizing our particles from around 200 to 100 nanometers and below. Our batch-to-batch reproducibility has improved ...
